AMPK activation via small-molecule treatment has been extensively studied, as clinically available drugs (salicylate and metformin) are widely used for treating conditions such as inflammation and diabetes, and are now being evaluated for their anti-tumorigenic properties (Hardie, 2014). Here, PRKAA1 is linked to diabetes mellitus.